Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221387 · ClinicalTrials.gov registry record · NA
Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03221387: Completed NA study, sponsored by Temple University.
NCT03221387 is a NA study that has completed, run by Temple University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03221387, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of using this therapy in the outpatient setting and its effects on sleep.
Primary Outcome
Number of hours of use of the device per day as recorded on the device
Interventions
- DEVICE Humidified nasal high flow with oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-10 |
| Est. Completion | 2019-12-15 |
| Phase | NA |
What the finished NCT03221387 record still lists
NCT03221387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Humidified nasal high flow with oxygen is the first listed.
NCT03221387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03221387 about?
NCT03221387 is a clinical study titled "Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients". Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of u...
What is the current status of trial NCT03221387?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-09-10. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT03221387?
The interventions under investigation include: Humidified nasal high flow with oxygen (DEVICE).
Who is sponsoring clinical trial NCT03221387?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03221387's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI